Pulmatrix (PULM) Upgraded by Zacks Investment Research to Buy

Pulmatrix (NASDAQ:PULM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company’s proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA. “

Several other research firms have also issued reports on PULM. HC Wainwright reiterated a “buy” rating on shares of Pulmatrix in a research report on Tuesday, April 16th. ValuEngine lowered shares of Pulmatrix from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.

Shares of PULM opened at $1.09 on Friday. Pulmatrix has a 12 month low of $0.72 and a 12 month high of $6.90. The company has a market cap of $8.35 million, a PE ratio of -0.22 and a beta of 1.68.

Pulmatrix (NASDAQ:PULM) last announced its earnings results on Tuesday, February 19th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.92. On average, research analysts predict that Pulmatrix will post -1.97 EPS for the current fiscal year.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Further Reading: Net Asset Value

Get a free copy of the Zacks research report on Pulmatrix (PULM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.